The FDA's Center for Drug Evaluation and Research released a preliminary year-in-review report that says the agency has cleared 26 new molecular entities this year.
Vaccine LU AF20513 is the their third Alzheimer's collaboration.
The company released two financial scenarios. The key is generic Copaxone.
Covidien is buying ingestible-camera company Given Imaging.
The drug is priced at $28,000 a month, before add-ons like ribivarin and (possibly) interferon.
The drug failed to hit its Phase III targets.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Chronic disease patients seek online support and information, and show little love for branded websites.
Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.
Spectrum DNA says its genetic services are at the ready, even if 23andMe's are not.